In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 16 2024
0mins
Should l Buy ?
Source: newsfilter
- Calliditas R&D Day: Calliditas Therapeutics AB will host an in-person and virtual R&D day on May 30, 2024, featuring discussions on their lead candidate setanaxib and the mode of action of TARPEYO.
- Speakers: The event will include presentations by Gareth J. Thomas and Jonathan Barratt, focusing on preclinical data, clinical trials, anti-fibrotic effects, and support for IgA nephropathy treatment.
- Program Highlights: Topics covered will include the NOX platform, squamous cell carcinoma of the head and neck, fibrotic diseases, and primary IgA nephropathy.
- Q&A Session: Following the presentations, there will be a live question and answer session for participants to engage with the speakers.
- Registration: Interested individuals must register in advance for the event and can submit questions for the Q&A session via email.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
